Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 33,083 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PLACEBO Clear all
Terminated Phase 4 Interventional Accepts healthy volunteers

Search to Advance Limited Use of Opioids Pilot: Optimization of Non-Opioid Therapy With a Steroid

NCT06074263
View directory record Official record
Conditions
Pain Management
Interventions
Dexamethasone 8mg, Placebo
Drug · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 99 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 21, 2026, 5:21 PM EDT
Recruiting Phase 3 Interventional

Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

NCT05877963
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Ublituximab, Placebo
Biological · Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
41
States / cities
Birmingham, Alabama • Cullman, Alabama • Orange, California + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 21, 2026, 5:21 PM EDT
Terminated Phase 2 Interventional Results available

Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)

NCT01226745
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
ONO-4641
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 55 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
20
States / cities
Tucson, Arizona • Aurora, Colorado • Fort Collins, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Oct 21, 2026, 5:21 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)

NCT03970837
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
GSK3196165 (Otilimab), Tofacitinib, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
1,764 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
64
States / cities
Flagstaff, Arizona • Glendale, Arizona • Mesa, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Oct 21, 2026, 5:21 PM EDT
Completed Phase 1 Interventional Results available

28-Day Daily-dose Crossover Study of the Safety and Tolerability of SB-121 (Lactobacillus Reuteri With Sephadex® and Maltose) in Subjects, Ages 15 to 45 Years, Diagnosed With Autistic Disorder

NCT04944901
View directory record Official record
Conditions
Autistic Disorder
Interventions
SB-121, Placebo
Drug
Lead sponsor
Scioto Biosciences, Inc.
Industry
Eligibility
15 Years to 45 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 25, 2024 · Synced Oct 21, 2026, 5:21 PM EDT
Recruiting Phase 2 Interventional

A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant

NCT05675930
View directory record Official record
Conditions
Graft-Versus-Host Disease, GVHD, Undefined
Interventions
Photobiomodulation Therapy, Placebo sham device
Device · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
4 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
9
States / cities
Bethesda, Maryland • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 21, 2026, 5:21 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Human Lung Responses to Respiratory Pathogens

NCT01967628
View directory record Official record
Conditions
Respiratory Infection
Interventions
Vitamin D3 (cholecalciferol), Placebo Sugar Pill
Dietary Supplement
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 60 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 21, 2026, 5:21 PM EDT
Completed Phase 2 Interventional Results available

Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

NCT01496365
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
DS-5565 tablet, pregabalin capsule, Placebo tablet, placebo capsule
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
78
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 21, 2026, 5:21 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Glycerol Phenylbutyrate Corrector Therapy For CF (Cystic Fibrosis)

NCT02323100
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ravicti low dose, Placebo
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Denver, Colorado • Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 21, 2026, 5:21 PM EDT
Withdrawn Phase 3 Interventional

A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

NCT01266811
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Placebo, Velcade and dexamethasone, Siltuximab, Velcade and dexamethasone
Drug · Biological
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
5
States / cities
Iowa City, Iowa • Boston, Massachusetts • Toledo, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2013 · Synced Oct 21, 2026, 5:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Cardiac Liability Study of Varegacestat in Healthy Participants

NCT06855264
View directory record Official record
Conditions
Healthy Volunteer
Interventions
varegacestat, Placebo, Moxifloxacin 400 mg
Drug
Lead sponsor
Immunome, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Oct 21, 2026, 5:21 PM EDT
Completed Phase 3 Interventional Results available

Pain Medicine for Wound Care Procedures

NCT00701909
View directory record Official record
Conditions
Wound Care, Pain Intensity, Hyperalgesia, Nausea, Vomiting, Hallucinations
Interventions
Morphine plus Ketamine, Morphine plus Saline (placebo)
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Oct 21, 2026, 5:21 PM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate the Safety and Efficacy of CP-690,550 in Patients With Moderate to Severe Crohn's Disease

NCT00615199
View directory record Official record
Conditions
Crohn's Disease
Interventions
CP-690,550, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
39
States / cities
Birmingham, Alabama • Mobile, Alabama • Boulder, Colorado + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2013 · Synced Oct 21, 2026, 5:21 PM EDT
Completed Phase 2 Interventional

Chemoprevention Therapy Plus Surgery in Treating Women With Breast Cancer

NCT00003099
View directory record Official record
Conditions
Breast Cancer
Interventions
Fenretinide, Tamoxifen Citrate, Placebo
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2003
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Oct 21, 2026, 5:21 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu)

NCT02727699
View directory record Official record
Conditions
Dementia, Alzheimer Type
Interventions
Xanamem™, Placebo (for Xanamem™)
Drug
Lead sponsor
Actinogen Medical
Industry
Eligibility
50 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
14
States / cities
Tucson, Arizona • Los Angeles, California • Poway, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 21, 2026, 5:21 PM EDT
Completed Not applicable Interventional

Efficacy of Sana Treatment in Fibromyalgia

NCT04568798
View directory record Official record
Conditions
Fibromyalgia
Interventions
Sana Sham Device
Device
Lead sponsor
Sana Health
Industry
Eligibility
18 Years to 65 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 21, 2026, 5:21 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease

NCT06226545
View directory record Official record
Conditions
Thyroid Eye Disease, Graves Ophthalmopathy, Graves Orbitopathy, Thyroid Associated Ophthalmopathy, Endocrine System Diseases, Orbital Diseases, Proptosis, Eye Diseases
Interventions
LASN01, Placebo
Drug
Lead sponsor
Lassen Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
10
States / cities
Beverly Hills, California • Palo Alto, California • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 21, 2026, 5:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Plasma Gelsolin in Healthy Volunteers

NCT05789745
View directory record Official record
Conditions
Volunteers, Healthy
Interventions
Recombinant human plasma gelsolin, placebo
Drug · Other
Lead sponsor
BioAegis Therapeutics Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 21, 2026, 5:21 PM EDT
Completed Phase 4 Interventional Results available

Progesterone Augmentation of Nicotine Replacement Therapy Study

NCT02685072
View directory record Official record
Conditions
Smoking Cessation
Interventions
Progesterone (200 mgs BID), Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 21, 2026, 5:21 PM EDT
Completed Phase 4 Interventional

Use of Ketorolac in Management of Post-Operative Pain After Heart Surgery

NCT00161577
View directory record Official record
Conditions
Pain Management Following Cardiopulmonary Bypass Surgery
Interventions
Ketorolac, Placebo
Drug · Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2009 · Synced Oct 21, 2026, 5:21 PM EDT
Completed Phase 2 Interventional

SCH-58235 (Ezetimibe) to Treat Homozygous Sitosterolemia

NCT00045812
View directory record Official record
Conditions
Lipoidosis
Interventions
SCH-58235
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 21, 2026, 5:21 PM EDT
Completed Not applicable Interventional Results available

Oxytocin and CBSST for People With Schizophrenia

NCT01752712
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
CBSST + Oxytocin, CBSST + Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 55 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
San Diego, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Oct 21, 2026, 5:21 PM EDT
Terminated Phase 2 Interventional Results available

Baminercept, a Lymphotoxin-Beta Receptor Fusion Protein, for Treatment of Sjögren's Syndrome

NCT01552681
View directory record Official record
Conditions
Primary Sjögren's Syndrome
Interventions
Baminercept, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • Hartford, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Oct 21, 2026, 5:21 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Vaginal Progesterone for the Prevention of Preterm Birth in Women With Arrested Preterm Labor

NCT01840228
View directory record Official record
Conditions
Premature Birth, Obstetric Labor, Premature
Interventions
Micronized progesterone suppository
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Oct 21, 2026, 5:21 PM EDT